The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
GvHD prophylaxis: novel strategies and future directions
Featured:
Mohamad Mohty
Ali Bazarbachi
Attilio Olivieri
Arnon Nagler
Robert Zeiser
Yi-Bin Chen
Amin Alousi
Mutlu AratDuring the GvHD Hub Steering Committee Meeting in October 2023, key opinion leaders met to discuss GvHD prophylaxis, including novel strategies and future directions. The recorded discussion was chaired by Professor Mohamad Mohty and featured Mutlu Arat, Ali Bazarbachi, Yi-Bin Chen, Amin Alousi, Arnon Nagler, Attilio Olivieri, and Robert Zeiser.
GvHD prophylaxis: novel strategies and future directions
The steering committee discussed how there is a need for the results from comparative trials in order to inform prophylaxis choices in clinical practice. The experts considered regimens involving combinations of post-transplant cyclophosphamide, tacrolimus, ruxolitinib, and mycophenolate mofetil, and how combinations could be optimized in immunosuppressed patients. The experts also discussed which prophylactic regimens they would use in cases of comorbidities.